Cipla subsidiaries incorporate wholly owned subsidiary in Mexico

Published On 2024-01-24 09:30 GMT   |   Update On 2024-01-24 09:35 GMT

Mumbai: Cipla has announced that Mexicip S.A. de C.V. ("Mexicip") has been incorporated as a wholly owned subsidiary ("WOS") in Mexico jointly by Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, WOS of the Company."We hereby notify that Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, wholly owned subsidiaries of the Company have jointly incorporated ‘Mexicip S.A. de...

Login or Register to read the full article

Mumbai: Cipla has announced that Mexicip S.A. de C.V. ("Mexicip") has been incorporated as a wholly owned subsidiary ("WOS") in Mexico jointly by Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, WOS of the Company.

"We hereby notify that Cipla (EU) Limited, UK and Cipla Holding BV, Netherlands, wholly owned subsidiaries of the Company have jointly incorporated ‘Mexicip S.A. de C.V.’, a wholly owned subsidiary in Mexico w.e.f. 22nd January, 2024," Cipla informed in a BSE filing.

Mexicip is incorporated with an objective of sale and distribution of pharmaceutical drugs in Mexico.

Read also: Cipla, Kemwell Biopharma, Manipal forge cell therapy alliance in US

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. Khwaja Abdul Hamied founded the Company in 1935 in Mumbai. Cipla has extended its presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. The Company is also deepening its presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Read also: Cipla reports 32 percent increase in net profit to Rs 1056 crore in Q3

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News